Literature DB >> 1378454

Levels of immunoglobulin G antibodies against defined epitopes of the L1 and L2 capsid proteins of human papillomavirus type 6 are elevated in men with a history of condylomata acuminata.

A Wikström1, C Eklund, G Von Krogh, P Lidbrink, J Dillner.   

Abstract

Sera from 159 men attending the sexually transmitted disease clinic at Karolinska Hospital, Stockholm, Sweden, were analyzed for the presence of immunoglobulin A (IgA) and IgG antibodies to a panel of synthetic peptides derived from the E2, L1, and L2 regions of the human papillomavirus types 1 (HPV 1), 6, 8, 11, 16, 18, 31, and 33. The study subjects were divided into three groups: (i) asymptomatic men with no history of genital warts who served as controls, (ii) men with visible condylomata, and (iii) men who had previously been afflicted with condylomata. There were no significant differences in antibody titers for any of the HPV 6- or 11-derived peptides among patients with current condylomata and the controls. For the peptide from L1 of HPV 6, there was an increase in the IgG titers among men with previous condylomata compared with the titers for the controls (52% versus 27% seropositivity; P less than 0.05). Also, for the peptide from L2 of HPV 6, there was an increase in the IgG titers among men who had been afflicted with condylomata previously (P less than 0.05). Increased IgA antibody titers against an HPV 16-derived peptide and an HPV 18-derived peptide were also detected. For the peptides from L1 and L2 of HPV 6, the study was extended to an additional group of 127 males attending the sexually transmitted disease clinic at Huddinge Hospital in southern Stockholm. Again, significantly increased antibody levels were detected only for IgG and only among asymptomatic men with a history of condylomata (P < 0.01 for the L1 peptide and P < 0.05 for the L2 peptide). The results suggest that the IgG response against the late proteins of HPV 6 reflects mainly previous exposure to the virus rather than ongoing viral disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1378454      PMCID: PMC265383          DOI: 10.1128/jcm.30.7.1795-1800.1992

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  37 in total

Review 1.  Heterogeneity of the human papillomavirus group.

Authors:  E M de Villiers
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

2.  Laboratory production in vivo of infectious human papillomavirus type 11.

Authors:  J W Kreider; M K Howett; A E Leure-Dupree; R J Zaino; J A Weber
Journal:  J Virol       Date:  1987-02       Impact factor: 5.103

3.  Expression in Escherichia coli of seven DNA fragments comprising the complete L1 and L2 open reading frames of human papillomavirus type 6b and localization of the 'common antigen' region.

Authors:  D G Strike; W Bonnez; R C Rose; R C Reichman
Journal:  J Gen Virol       Date:  1989-03       Impact factor: 3.891

4.  A synthetic peptide defines a serologic IgA response to a human papillomavirus-encoded nuclear antigen expressed in virus-carrying cervical neoplasia.

Authors:  J Dillner; L Dillner; J Robb; J Willems; I Jones; W Lancaster; R Smith; R Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

5.  High prevalence rate of human papillomavirus infection and association with abnormal papanicolaou smears in sexually active adolescents.

Authors:  W D Rosenfeld; S H Vermund; S J Wentz; R D Burk
Journal:  Am J Dis Child       Date:  1989-12

6.  Antibodies against the human papillomavirus type 16 early proteins in human sera: correlation of anti-E7 reactivity with cervical cancer.

Authors:  I Jochmus-Kudielka; A Schneider; R Braun; R Kimmig; U Koldovsky; K E Schneweis; K Seedorf; L Gissmann
Journal:  J Natl Cancer Inst       Date:  1989-11-15       Impact factor: 13.506

7.  Further evaluation of the prognostic value of morphometric and flow cytometric parameters in breast-cancer patients with long follow-up.

Authors:  A M Uyterlinde; J P Baak; N W Schipper; H Peterse; E Matze; C J Meijer
Journal:  Int J Cancer       Date:  1990-01-15       Impact factor: 7.396

8.  Human papillomavirus infections in women with and without abnormal cervical cytology.

Authors:  E M de Villiers; D Wagner; A Schneider; H Wesch; H Miklaw; J Wahrendorf; U Papendick; H zur Hausen
Journal:  Lancet       Date:  1987-09-26       Impact factor: 79.321

9.  Advantage of human papillomavirus typing in the clinical evaluation of genitoanal warts. Experience with the in situ deoxyribonucleic acid hybridization technique applied on paraffin sections.

Authors:  G von Krogh; S M Syrjänen; K J Syrjänen
Journal:  J Am Acad Dermatol       Date:  1988-03       Impact factor: 11.527

10.  Identification of immunoreactive antigens of human papillomavirus type 6b by using Escherichia coli-expressed fusion proteins.

Authors:  S A Jenison; J M Firzlaff; A Langenberg; D A Galloway
Journal:  J Virol       Date:  1988-06       Impact factor: 5.103

View more
  4 in total

1.  Oral human papillomavirus infection in men might contribute to HPV serology.

Authors:  S Syrjänen; T Waterboer; K Kero; J Rautava; K Syrjänen; S Grenman; M Pawlita
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-08-14       Impact factor: 3.267

2.  Antibodies against papillomavirus antigens in cervical secretions from condyloma patients.

Authors:  L Dillner; A Fredriksson; E Persson; O Forslund; B G Hansson; J Dillner
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

3.  A prospective study of antibody responses to defined epitopes of human papillomavirus (HPV) type 16 in relationship to genital and anorectal presence of HPV DNA.

Authors:  G J Van Doornum; M Prins; L Pronk; R A Coutinho; J Dillner
Journal:  Clin Diagn Lab Immunol       Date:  1994-11

4.  Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments.

Authors:  T Yamada; C M Wheeler; A L Halpern; A C Stewart; A Hildesheim; S A Jenison
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.